INSM
INSMED Inc
NASDAQ · Healthcare · Biotechnology · US
$120.00
−3.21%Next report
Analyst consensus
- Next report date
- Oct 29, 2026
- EPS estimate
- -$0.37
- Revenue estimate
- $496.5M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.06
- EPS estimate
- -$0.67
- Revenue actual
- $425.5M
- Revenue estimate
- $387.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 9
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +7.8%
- Revenue beats (12Q)
- 9
Analyst ratings
Sell-side consensus
- Consensus
- Strong Buy
- Price target
- $186
- PT range
- $169 – $205
- Analysts
- 7
7 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.67 | -$0.06 | Beat 91.08% | $425.5M |
| May 7, 2026 | -$0.90 | -$0.76 | Beat 15.56% | $306.0M |
| Feb 19, 2026 | -$1.07 | -$1.54 | Miss -43.93% | $263.8M |
| Oct 30, 2025 | -$1.33 | -$1.75 | Miss -31.58% | $142.3M |
| Aug 7, 2025 | -$1.30 | -$1.70 | Miss -30.77% | $107.4M |
| May 8, 2025 | -$1.34 | -$1.42 | Miss -5.97% | $92.8M |
| Feb 20, 2025 | -$1.17 | -$1.32 | Miss -12.82% | $104.4M |
| Oct 31, 2024 | -$1.20 | -$1.27 | Miss -5.83% | $93.4M |
| Aug 8, 2024 | -$1.24 | -$1.94 | Miss -56.45% | $90.3M |
| May 9, 2024 | -$1.24 | -$1.06 | Beat 14.52% | $75.5M |
| Feb 22, 2024 | -$1.13 | -$1.28 | Miss -13.27% | $83.7M |
| Oct 26, 2023 | -$1.06 | -$1.10 | Miss -3.77% | $79.1M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 29, 2026